Drug Type Small molecule drug |
Synonyms- |
Target |
Action blockers |
Mechanism HCN channels blockers(Hyperpolarization-activated cyclic nucleotide-gated channel blockers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H38N2O9S |
InChIKeyBTPJWGWDKZFLCT-ZMBIFBSDSA-N |
CAS Registry1202000-62-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ivabradine Sulfate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic heart failure | Phase 3 | China | 08 Aug 2014 | |
Chronic systolic heart failure | Phase 3 | China | 01 May 2014 | |
Angina, Stable | Phase 1 | China | 15 Apr 2018 |
Phase 2/3 | 360 | dpaeejryde(codsxrpsqj) = After 32 weeks, a significant improvement of LV end-systolic volume index from baseline was observed in both arms with a greater effect in the ivabradine SR arm. zqmhtwllsj (iszigmiwol ) View more | Positive | 09 Aug 2022 | |||
Placebo |